Day: March 14, 2024

Fourth Quarter Financial Highlights: (comparisons are year over year)Total revenues increased 21.7% year over year to $521.5 million Construction and Material Handling revenues of $328.1 million and $179.0 million, respectively Product support revenues increased 14.2% year over year with Parts sales increasing to $69.1 million and Service revenues increasing to $60.8 million New and used equipment sales grew 25.1% to $298.1 million Net loss available to common stockholders of $(2.7) million compared to $(1.5) million in 2022 Basic and diluted net loss per share of $(0.08) compared to $(0.05) in 2022 Adjusted basic and diluted net income per share* of $0.03 for 2023 compared to $0.10 for 2022 Adjusted EBITDA* grew 16.4% to $49.7 million compared to $42.7 million in 2022 Completed acquisitions of Burris Equipment Company and Ault Industries...

Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update. Q3 FY2024 and Recent Accomplishments HeartSciences has seen a fundamental change in its business opportunity since the end of the second fiscal quarter, with material improvements to its financial position and outlook. A summary of the main changes and business highlights during Q3 FY2024 and to date include:Strategic shift from a Company with a single-device, single-algorithm...

Record Full Year Gross Margin and Net Income as Business Continues to Expand CHINO, Calif., March 14, 2024 (GLOBE NEWSWIRE) — Karat Packaging Inc. (Nasdaq: KRT) (“Karat” or the “Company”), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced financial results for its fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 HighlightsFourth quarter 2023 financial results included:Change of estimate on import duty reserve totaling $2.3 million, an increase to cost of goods sold. Write-off of $1.1 million of a vendor prepayment upon the resolution of a legal contingency, an increase to general and administrative expenses. Out-of-period tax adjustment of $0.3 million, an increase to provision for income taxes. Misclassification...

Growth Rate Exceeded the Industry by an Estimated 750 bps in 2023Exceeded Profitability Expectations and Increased 2023 Gross Margin by 430 bps to 57.6%Generated 2023 GAAP Diluted EPS of $0.04 and 2023 Adjusted Diluted EPS of $0.17Provides Q1 and Full Year 2024 Guidance SAN FRANCISCO, March 14, 2024 (GLOBE NEWSWIRE) — Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (Nasdaq: BRLT), an innovative, global leader in ethically sourced fine jewelry, today announced financial results for the three and twelve months ended December 31, 2023. Fourth Quarter and Fiscal Year 2023 Highlights (quarterly and annual periods ended December 31, 2023):Delivered record net sales of $124.3 million and $446.4 million in the fourth quarter and fiscal year, respectively Growth rate exceeded the industry by an estimated 750 basis points...

Full year 2023 record Net Revenue of $317.3 million, an increase of 28.0% year-over-year Full year 2023 Gross Profit margin of 50.3%, a 930 basis-point improvement year-over-year Full year 2023 Adjusted EBITDA from continuing operations1 of $68.8 million, an increase of 77.1% year-over-year Delivered first full year of both positive Cash Flow from continuing operations and Free Cash Flow2 TORONTO, March 14, 2024 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND, OTCQX: TSNDF), a leading North American cannabis company, today reported its financial results for the fourth quarter and full year ended December 31, 2023. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise. The following financial measures are reported...

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) — Getty Images Holdings, Inc. “Getty Images” or the “Company”) (NYSE: GETY), a preeminent global visual content creator and marketplace, today reported financial results for the fourth quarter and full year ended December 31, 2023. “In a difficult 2023, Getty Images continued to lay a strong foundation grounded in our core value propositions of helping our customers create at a higher level, saving them time and money and eliminating risk,” said Craig Peters, Chief Executive Officer at Getty Images. “Central to this foundation is Getty Images’ high-quality content and coverage derived from industry-leading talent, committed and long-standing partnerships, exclusive access, extensive research and rare expertise.” “In 2023, we remained fiscally disciplined, generated healthy levels of free...

Evoke Pharma, Inc.Balance SheetEvoke Pharma, Inc.Statement of OperationsFiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and recent corporate developments. “In 2023, we focused on operational excellence to expand GIMOTI’s market share and ensure its availability for patients requiring an improved gastroparesis treatment. Our commercial team’s dedicated efforts...

$123.6 million net revenue hits a three-year high, marking a return to profitability JINHUA, China, March 14, 2024 (GLOBE NEWSWIRE) — Kandi Technologies Group, Inc. (the “Company”, “we” or “Kandi”) (NASDAQ GS: KNDI), today announced its financial results for the full year ended December 31, 2023. Full Year 2023 HighlightsTotal net revenues increased by 4.9% to $123.6 million, from $117.8 million in 2022. As the primary driver of total revenue, off-road vehicles and associated parts sales increased by 51.5% to $107.0 million from $70.6 million in 2022. Gross profit increased by 112% to $41.4 million, from $19.5 million in 2022. Net income was $1.7 million, or $0.02 income per fully diluted share, compared to a net loss of $12.9 million, or $0.17 loss per fully diluted share for 2022. The Company has a strong working capital position....

Deployed the 84-qubit Ankaa™-2 quantum computer, with a 2.5X improvement in error performance compared to the Company’s previous QPUs and achieved a 98% median 2-qubit fidelity. Won competition to develop and deliver a 24-qubit quantum computing system to the UK’s National Quantum Computing Centre (NQCC). Launched the Novera™ QPU, a 9-qubit quantum processor unit available for integration into customers’ on-premise systems. Announces second Novera QPU sale to the Air Force Research Lab (AFRL).BERKELEY, Calif., March 14, 2024 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the fourth quarter and year ended December 31, 2023. Fourth Quarter and Full Year 2023 Financial HighlightsTotal...

Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in second half of 2024 Cash, cash equivalents and marketable securities of $263 million, expected to provide runway into 2026 FOSTER CITY, Calif., March 14, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided corporate updates. “I joined Terns last month at a pivotal stage in the company’s...